Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 20, 1988 - Issue sup56
Submit an article Journal homepage
11
Views
0
CrossRef citations to date
0
Altmetric
Miscellany

Recent Developments in the Clinical Use of Norfloxacin

S. Ragnar Norrby
Pages 1-58 | Published online: 02 Jan 2015

Reference

  • King A, Phillips I. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother 18 ( Suppl. D): 1–20, 1986

References

  • Bergan T, Lolekha S, Cheong MK, Poh CL, Doenchan S, Charoenpipop D. Effect of recent antibacterial agents against bacteria causing diarrhoea. Scand J Infect Dis, Suppl. 56: 7–10, 1988
  • Lolekha S, Patanacharoen S, Thanangkul B, Vibulbandhitkit S. Norfloxacin versus trimethoprim/sulphamethoxazole in the treatment of acute bacterial diarrhoea: A placebo controlled study. Scand J Infect Dis, Suppl. 56: 35–45, 1988
  • Swanson BN, Bopparia KK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing doses. Antimicrob Agents Chemother 23: 284–288, 1983
  • Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton, Illinois: Drug Intelligence Publications, 403–437, 1975
  • Chen RRL. Huang JD, Hsieh WC. Pharmacokinetics of norfloxacin in healthy Chinese volunteers. J Am Med Ass SE Asia 30 (Special Suppl.): 30–32, 1986

References

  • Young LS. Gram-negative bacillary colonization and bacteraemia in the compromised host. Infection 10: 319–323, 1982
  • van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: Colonization-controlling mechanisms and consequences for antibiotic treatment. Infection 11. Suppl. 2: 90–92, 1983
  • Nord CE, Kager L, Heimdahl A. Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med 76: 99–106, 1984
  • Heimdahl A, Nord CE. Colonization of the oropharynx with pathogenic microorganisms–a potential risk factor for infection in compromised patients. Chemotherapia 4: 186–191, 1985
  • Hentges D, Stein A, Casey S, Que J. Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: Influence of antibiotics on colonization resistance. Infect Immun 47: 118–122. 1985
  • Barza M, Giuliano M, Jacobus N, Gorbach S. Effect of broad-spectrum parenteral antibiotics on “colonization resistance” of intestinal microflora of humans. Antimicrob Agents Chemother 31: 723–727, 1987
  • Wolfson JS, Hooper DC. Minireview: The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–586, 1985
  • Shannon K, Phillips I. The antimicrobial spectrum of the quinolones. Clin Res Forum 7: 29–36 1985
  • Lee C, Ronald A. Norfloxacin: Its potential in clinical practice. Am J Med 82: 27–34, 1987
  • Meckenstock R, Haralambie E. Linzenmeier G, Wendt F. Die Beeinflussung der Darmflora durch Norfloxacin bei gesunden Menschen. Z Antimikr Antineoplast Chemother 1: 27–34, 1985
  • Schaeffer A, Sisney G. Efficacy of norfloxacin in urinary tract infections: Biological effects on vaginal and fecal flora. J Urol 133: 628–630, 1985
  • De Vries-Hospers HG, Welling GW, van der Waaij D. Norfloxacin for selective decontamination. A study in human volunteers. Prog Clin Biol Res 81: 259–262, 1985
  • Leigh DA, Emmanuel FXS. Tighe C. Hancock P. Boddy S. Pharmacokinetic studies of norfloxacin in healthy volunteers and effect on the faecal flora. In: Ishigami J, ed. Recent advances in chemotherapy. Kyoto: Antimicrobial Section 2. Proc. 14th International Congress of Chemotherapy, 1935–1836, 1985
  • Pecquet S, Andremont A, Tancrède C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human faecal flora. Antimicrob Agents Chemother 29: 1047–1052, 1986
  • Edlund C, Bergan T, Josefsson K, Solberg R, Nord CE. Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scand J Infect Dis 19: 113–121, 1987
  • Cofsky R, du Bouchet L, Landesman S. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Karp J, Merz W, Hendricksen C. Laughon B, Redden T, Bamberger B, Bartlett J, Saral R, Burke P. Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 106: 1–7, 1987
  • Winston D, Ho W, Karp J, Bartlett J, Finley R, Joshi J, Talbot G, Levitt L. Deresinski S. Corrado M. Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med 82: 40–46, 1987
  • van Griethuysen AJA, Clasener HAL, Vollaard EJ, Niessen M. Colonization resistance: A guide to antibiotic policy in the ICU. Infect Contr 8: 269–270, 1987
  • Boerema JBJ, Olthof BJ, van Saene HKF. Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. Scand J Infect Dis, Suppl. 48: 27–31, 1986
  • Westenfelder M, Pelz K, Frankenschmidt A, Vahlensieck W. Klinische Prüfung der Effektivität und Verträglichkeit von Norfloxacin in der Therapie komplizierter Harnwegsinfektionen und in der Langzeitprophylaxe rezidivierender Harnwegsinfektionen. Infection 15: 20–24, 1987
  • van Saene JJM, van Saene HKF, Stoutenbeek CP, Lerk CF. Influence of faeces on the activity of antimicrobial agents used for decontamination of the alimentary canal. Scand J Infect Dis 17: 295–300, 1985
  • Goldstein E, Citrn D, Corrado M. Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Am J Med 82: 84–87, 1987

References

  • Reeves DS, Bint AJ, Bullock DW. Sulphonamides, co-trimoxazole, and tetracyclines. Br Med J 2: 410–413, 1978
  • Ellis-Pegler RB. Antimicrobial therapy in general practice. Medical Progress May: 15–20, 1981
  • Gruneberg RN, Smellie JM, Leakey A, Atakin WS. Long-term low-dose co-trimoxazole in prophylaxis of childhood urinary tract infection: Bacteriological aspects. Br Med J 2: 206–208, 1976
  • Garrod LP. Chemoprophylaxis. Br Med J 4: 561–564, 1975
  • O'Grady FW. Chemoprophylaxis in medicine and surgery. J R Coll Physicians London 6, SNo. 2, 1976
  • Hills NH, Bultitude MI, Eykyn S. Co-trimoxazole in prevention of bacteriuria after prostatectomy. Br Med J 2: 497–499, 1976
  • The Study Group on the Use of Antimicrobial Drugs. Prophylactic antimicrobial drug therapy at five London Teaching Hospitals. Lancet i: 1351–1353, 1977
  • Benbrook DM, Miller RV. Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob Agents Chemother 29: 1–6, 1986
  • Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother 13 ( Suppl B): 9–23, 1984
  • Bergan T. Quinolones. Antimicrobial Agents Annual 2. Chapter 15, 1987
  • Boerema JBJ, Olthof BJ, Van Saene KF. Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. Scand J Infect Dis Suppl 48: 27–31, 1986
  • Boerema JBJ, Van Saene KF. Norfloxacin treatment in complicated urinary tract infection. Scand J Infect Dis Suppl 48: 20–26, 1986
  • Cherubin C, Stilwell S. Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms. Scand J Infect Dis Suppl 48: 32–37, 1986
  • Sabbaj J, Hoagland VL, Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis Suppl 48: 48–53, 1986
  • Wang C, Sabbaj J, Corrado M, Hoagland V. Worldwide clinical experience with norfloxacin: Efficacy and safety. Scand J Infect Dis Suppl 48: 81–89, 1986
  • Kass EH. Asymptomatic infection of the urinary tract. Trans Assoc Am Physicians 69: 56–64, 1956
  • Lee KH, Wong WT. Asymptomatic bacteriuria in Chinese pregnant women. Bull Hong Kong Med Assoc 22: 81–86, 1970
  • Wing AJ. Infections of the urinary tract: Diagnosis. Br Med J 3: 753–755, 1970
  • National Committee for Clinical Laboratory Standards (NCCLS). Approved Standard: ASM-2, 1979
  • Brumfitt W, Hamilton-Miller JMT. A review of the problem of urinary tract infection management and the evaluation of a potential new antibiotic. J Antimicrob Chemother 13 ( Suppl B): 121–133, 1984
  • Haase D, Urias B, Harding G, Ronald A. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Eur J Clin Microbiol 2: 235–241, 1983
  • Haase DA, Harding GKM, Thomson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localised, acute symptomatic urinary tract infections and antimicrobial effect on periurethral and faecal microflora. Antimicrob Agents Chemother 26: 481–484, 1984
  • Cofsky RD, DuBouchet L, Landesman SH. Recovery of norfloxacin in faeces after administration of single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984

References

  • Bergan T. Norfloxacin: Antibacterial activity in comparison with other quinolones. JAMA SEA 2 ( Spec Suppl.): 8–14, 1986
  • Kahn MY, Gruniger RP, Nelson S, Klicker RE. Comparative in-vitro activity of norfloxacin and ten other oral antimicrobial agents against urinary tract bacterial isolates. Antimicrob Agents Chemother 12: 670–672, 1982
  • Giamarellou H, Tsargarakis J, Petrikkos G, Daikos GK. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol 2: 266–269, 1983
  • Sabbaj J, Hoagland VL, Shih WJ. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infection. Antimicrob Agents Chemother 27: 297–301, 1985
  • Watt B, Chait I, Kelsey MC, . Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infection–a multi-centre trial. J Antimicrob Chemother 13 ( Suppl. B): 89–94, 1984
  • Barry AL, Thornsbery C. Susceptibility Tests–Diffusion Test Procedure. In: Lennette EH eds. Washington DC: American Society for Microbiology, 978–987, 1985
  • Shungu DL, Weinberg E, Gadebusch HH. Tentative interpretive standards for disc diffusion susceptibility testing with norfloxacin (MK-0366, AM-715). Antimicrob Agents Chemother 23: 256–260, 1983
  • Haase D, Urias B, Harding G, Ronald A. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Eur J Clin Microbiol 2: 235–241, 1983
  • Murray BE, Rensimer ER, Dupont HL. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfamethoxazole. N Engl J Med 306: 130–135, 1982
  • Towner KJ, Pearson NJ, Pinn PA, O'Grady F. Increasing importance of plasmid-mediated trimethoprim resistance in enterobacteria: Two six-month clinical surveys. Brit Med J 280: 517–519, 1980
  • Bendall MJ. A review of urinary tract infection in the elderly. J Antimicrob Chemother 13 ( Suppl B): 69–78, 1984
  • Porter GA. Renal Function Tests. In: Bennett WM, Porter GFA, Bagby SP, McDonald WJ, eds. Drugs and Renal Diseases, New York: Churchill Livingstone, 1–12, 1978

References

  • Phonboon K. Kunasol P. Chayaniyayodhin T. Srisomporn D. Surveillance of diarrhoeal diseases in Thailand. Bull WHO 64: 715–720, 1986
  • Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 23: 86–90, 1983
  • Carlson JR, Thornton SA, DuPont HL, West AH, Mathewson JJ. Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother 24: 509–513, 1983
  • Cofsky RD, DuBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Lolekha S, Patanacharoen S. Clinical and microbiological efficacy of norfloxacin in acute diarrhea. Rev Infect Dis 10 ( Suppl): S210–211, 1988
  • Bergan T, Lolekha S, Cheong MK, Poh LP, Doencham S, Charoenpipop D. Effect of recent antibacterial agents against bacteria causing diarrhoea. Scand J Infect Dis Suppl. 56: 7–10, 1988
  • Pitarangsi C, Echeverria P, Whitmore R . Enteropathogenicity of Aeromonas hydrophila and Plesiomonas shigelloides: Prevalence among individuals with and without diarrhea in Thailand. Infect Immun 35: 666–673, 1982
  • Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull WHO 36: 871–883, 1967
  • Haltalin KC, Nelson JD, Ring R III, Sladoje M, Hinton LV. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 70: 970–981, 1967
  • DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG. Treatment of travellers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 307: 841–844, 1982
  • Nelson JD, Kusmiesz H, Jackson LH, Woodman E. Trimethoprim/sulfamethoxazole therapy for shigellosis. JAMA 235: 1239–1243, 1976
  • Johnson PC, Ericsson CD, Morgan DR, DuPont HL, Cabada FJ. Lack of emergence of resistant fecal flora during successful prophylaxis of travellers' diarrhea with norfloxacin. Antimicrob Agents Chemother 30: 671–674, 1986
  • Pichler HET, Diridl G, Stickler K, Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 82 ( S4A): 329–332, 1987
  • Ruiz-Palacios GM. Norfloxacin in the treatment of bacterial enteric infections. Scand J Infect Dis Suppl 48: 55–63, 1986
  • Ericsson CD, Johnson PC, DuPont HL, Morgan DR, Bitsura JAM . Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travellers' diarrhea. Ann Intern Med 106: 216–220, 1987
  • Wiström J, Norrby SR, Jellheden B, Englund G. Norfloxacin for prevention of travellers' diarrhea: A double-blind, placebo controlled study (Abstract). Congress on bacterial and parasitic drug resistance, Dec 10–13, 1986, Bangkok, Thailand: 217
  • DuPont HL, Corrado ML, Sabbaj J. Use of norfloxacin in the treatment of acute diarrheal disease. Am J Med 82 ( Suppl 6B): 79–83, 1987

References

  • Goosens H, de Mol P. Coignau H, Levy J, Grados O, Ghysels G, Innocent H, Butzler JP. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against entropathogens. Antimicrob Agents Chemother 27: 388–392, 1985
  • Perblud SR, Gill CJ, Campos JM. Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp. Antimicrob Agents Chemother 25: 327–330, 1984

References

  • Swanson BN, Bopanna VK, Vlassess PH, . Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 23: 284–288, 1983
  • Bergan T. Norfloxacin: Pharmacokinetics in comparison with other quinolones. JAMA SEA 2 ( Spec. Suppl.): 3–7, 1986
  • Velmonte MA, Apepe T, Costa C, . Efficacy and safety of norfloxacin in uncomplicated gonorrhoea. JAMA SEA 2 ( Spec. Suppl.): 49–53, 1986
  • Crider Z, Steven R, Steven D, . Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N Engl J Med 311: 137–140, 1984
  • Kaplowitz LG, Vishniavsky N, Evans A, . Norfloxacin compared with ampicillin and probenecid for the therapy of gonorrhoea. 6th International Meeting of the International Society for STD Research, 31st July–2nd August 1985; Brighton, England, Abstract P111.
  • Panikabutra K, Ariyarit C, Chitwarakorn A, . Norfloxacin in the treatment of uncomplicated gonorrhoea. JAMA SEA 2 ( Spec. suppl.): 45–48, 1986
  • Lee CT, Thirumoorthy T, Lim KB, . Norfloxacin in the treatment of uncomplicated gonorrhoea in Singapore males. JAMA SEA 2 ( Spec. Suppl.): 42–44, 1986
  • Romanowski B, Wood H, Draker J, . Norfloxacin in the therapy of uncomplicated gonorrhoea. Antimicrob Agents Chemother 30: 514–515, 1986
  • Bogaerts J, Tello WM, Verbist L, . Norfloxacin versus Thiamphenicol for treatment of uncomplicated gonorrhoea in Rwanda. Antimicrob Agents Chemother 31: 434–437, 1987
  • Panikabutra B, Lee CT, Ho B, . Efficacy and safety of norfloxacin in uncomplicated gonorrhoea caused by NPPNG or PPNG in comparison with Spectinomycin. Accepted for publication by Genitourinary Medicine.
  • Sakai S, Kumamoto Y, Tsunekawa T, . Epidermiologic and therapeutic study on gonococcal infections–clinical efficacy of norfloxacin. J Urology (Japanese) 32: 1747–1761, 1986
  • Saito I, Terada Y, Yokozawa M, . Bacteriological and clinical study of norfloxacin in the treatment of gonococcal urethritis. West Japan J Urology (Japanese) 48: 2697274, 1986
  • Polnikorn N. Treatment of disseminated gonococcal infection with oral norfloxacin: A case report. J Thai Med Soc STD 3: 37–38, 1986
  • Sng EH, Yeo KL, Rajan VS. Simple method for detecting penicillinase-producing Neisseria gonorrhoeae and Staphylococcus aureus. Br J Vener Dis 57: 141–142, 1981
  • Thornsberry C, Gavern TL, Gerlach EH. New developments in antimicrobial susceptibility testing. Cumitech 6: 1–2, 1977
  • Perine PL, Morton RS, Piot P, . Epidemiology and treatment of penicillinase-producing Neisseria gonorrhoeae. Sex Transm Dis 6 ( Suppl.): 152–158, 1979
  • Osoba AO. Sexually transmitted diseases in tropical Africa. A review of the present situation. Br J Vener Dis 57: 89–94, 1981
  • Greaves W, Strine P, Schrader M, . Penicillinase-producing Neisseria gonorrhoeae: The continuing challenge. 5th International Meeting of the International Society for STD Research, 1st–3rd August 1983, Seattle, Washington, USA, Abstract 15.
  • Ison CA, Eason CSF, Bellinger CM, . Changes in the epidemiology of penicillinase-producing Neisseria gonorrhoeae between 1978 and 1982 in a large London clinic. Abstract, 5th International Meeting of the International Society for STD Research. 1st–3rd August 1983, Seattle, Washington, USA
  • Eason CSF, Ison CA, Bellinger CM, . Emergence of resistance after spectinomycin treatment for gonorrhoea due to beta-lactamase producing strains of N gonorrhoeae. Br J Med 284: 1604–1605, 1982
  • Patefield AJ, Westbrook WG, Johnston NA. Spectinomycin resistant Neisseria gonorrhoeae–Worldwide. MMWR 31: 632, 637, 638, 1982
  • Jones O, Strohmeyers G, Brocket J, . Spectinomycin-resistant penicillinase producing Neisseria gonorrhoeae. MMWR 32: 51–52, 1983
  • Judson FN. Treatment of uncomplicated gonorrhoea with ceftriaxone: A review. Sex Transm Dis 15, S3 (Suppl.): 199–202, 1986
  • Rajan VS, Sng EH. Carbenicillin indanyl sodium in the treatment of gonorrhoea. Sing Med J 15: 37–39, 1974
  • Rajan VS. Instant treatment of gonorrhoea in Singapore. Sing Med J 13: 198–200, 1972
  • Rajan VS, Tan NJ, Khoo R, . Treatment of gonorrhoeae–the Singapore experience. Asian J Infect Dis 1: 71–72, 1977
  • Franceschinis R. International symposium on thiamphenicol and sexually transmitted disease (Suppl.), JB Lippincott Co, 11: 376–425, 1984
  • Lim KB, Rajan VS, Giam YC, . Treatment of uncomplicated gonorrhoea with rosoxacin (acrosoxacin). Br J Vener Dis 60: 157–160, 1984
  • Lim KB, Rajan VS, Giam YC, . Two dose Augmentin treatment of acute gonorrhoea in men. Br J Vener Dis 60: 161–163, 1984
  • Rice RJ, Thompson SE. Treatment of uncomplicated infections due to Neisseria gonorrhoeae. JAMA 13: 1739–1746, 1986

References

  • Annual report, VD Division, Dept of CDC, Ministry of Public Health, Thailand 1986
  • Taylor DN, Duangmani C, Suvongse C, O'Connor R, Pitarangsi C, Panikabutra K, Echeverria P. The role of Haemophilus ducreyi in penile ulcers in Bangkok, Thailand. Sex Transm Dis July–Sept: 148–151, 1984
  • Schmid GP. The treatment of chancroid. JAMA 255, No 13: 1757–1762, 1986
  • Bowmer MI, Nsanze H, D'Costa LJ, Dylewski J, Fransen L, Piot P, Ronald AR. Single-dose ceftriaxone for chancroid. Antimicrob Agents Chemother 31: 67–69, 1987
  • Fransen L, Nsanze H, Ndinya-Achola J, D'Costa L, Ronald AR, Piot P. A comparison of single-dose Spectinomycin with five days of trimethoprim-sulfamethoxazole for the treatment of chancroid. Sex Transm Dis April–June: 98–101 1987
  • Naamara W, Plummer FA, Greenblatt M, D'Costa LJ, Ronald AR. Treatment of chancroid with ciprofloxacin. Am J Med 82 ( Suppl 4 A): 317–320, 1987
  • Mensing H. Treatment of chancroid with enoxacin. Acta Derm Venereol (Stockh) 65: 455–457, 1985
  • Sturm AW. Comparison of the antimicrobial susceptibility patterns of fifty-seven strains of Haemophilus ducreyi isolated in Amsterdam from 1978 to 1985. J Antimicrob Chemother 19: 187–191, 1987
  • Taylor DN, Echeverria P, Hanchalay S, Pitarangsi C, Slootmans L, Piot P. Antimicrobial susceptibility and characterisation of outer membrane proteins of Haemophilus ducreyi isolated in Thailand. J Clin Microbiol 21: 442–444, 1985
  • Haase DA, Ndinya-Achola JO, Nash RA, D'Costa LJ, Hazlett D, Lublvama S, Nsanze H, Ronald AR. Clinical evaluation of rosoxacin for the treatment of chancroid. Antimicrob Agents Chemother 30: 39–41, 1986
  • Panikabutra K, Lee CT, Velmonte M, Bamberg P. Efficacy and safety of norfloxacin in uncomplicated gonorrhoea—a double-blind dose response study. Asean symposium on quinolones in the treatment of gonorrhoea, JAMA Special Supplement, Congress Archives 86001: 54–56, April 1986
  • Bergan T. Norfloxacin: antibacterial activity in comparison with other quinolones. Asean symposium on quinolones in the treatment of gonorrhoea, JAMA Special Supplement, Congress Archives 86001: 8–14, April 1986
  • Ripa KT, Mårdh PA. Cultivation of Chlamydia trachomatis in cycloheximide-treated Macoy cells. J Clin Microbiol 6: 328–331, 1977
  • Bodhidatta L, Taylor DN, Kuvanont K, Echeverria P. Evaluation of single dose and double dose regimens of ciprofloxacin for the treatment of chancroid in a randomized double blind clinical trial. Armed forces Research Institute of Medical Sciences, Thailand (in press)
  • Taylor DN, Pitarangsi C, Echeverria P, Panikabutra K, Suvongse C. Comparative study of ceftriaxone and trimethoprim-sulfamethoxazole for the treatment of chancroid in Thailand. J Infect Dis 152: 1002–1006, 1985

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.